The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Gusev E.I.

Pirogov Russian National Research Medical University (Pirogov University)

Martynov M.Yu.

Pirogov Russian National Research Medical University (Pirogov University);
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

Stroke: current state of the problem

Authors:

Gusev E.I., Martynov M.Yu.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(11): 7‑18

DOI: 10.17116/jnevro20241241117

Read: 3252 times

Download PDF (RU)
Contact the author
Table of contents

STROKE: CURRENT STATE OF THE PROBLEM
STROKE: CURRENT STATE OF THE PROBLEM

To cite this article:

Gusev EI, Martynov MYu. Stroke: current state of the problem. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(11):7‑18. (In Russ.)
https://doi.org/10.17116/jnevro20241241117

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Primary progressive apha­sia in the neurologist practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):61-66
Cognitive impairment after major surgical operations. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):74-80
The known and new ideas about the mechanism of action and the spectrum of effe­cts of Mexi­dol. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):22-33
Therapeutic pote­ntial of quercetin and its deri­vatives against COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):44-50
Prevalence and characteristics of risk factors for cere­brovascular disease in overweight. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):118-124
Targets of rational neuroprotection in the therapy of chro­nic cere­bral ischemia and the possibilities of achieving them. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):96-101
Early anti­thrombotic protection of the brain in patients with ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):5-10
Current approaches to the prevention and treatment of post-thrombotic syndrome. Russian Journal of Preventive Medi­cine. 2025;(5):111-116
Prevention of repe­rfusion injury in cardiac surgery. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(4):471-477
Prediction of restoration of functional acti­vity of pare­tic limbs in patients who have suffered an ischemic stroke. Problems of Balneology, Physiotherapy and Exercise Therapy. 2025;(3):31-40
Abstract:

We review the current and emerging topics in ischemic stroke (IS) and intracerebral hemorrhage (ICH). We discuss the association of genetic predisposition and healthy lifestyle, ambient particulate air pollution, weather parameters, variations in the anatomy of cerebral blood vessels, psychological stress, depression, insonmia with the development of IS or ICH. Also, the role of oral anticoagulants (AC) as a new risk factor for ICH is presented. The issues of pathophysiology of IS and ICH are considered, in particular, the discrepancy between blood flow and metabolism and penumbra stability in IS and changes in perfusion and cerebral blood flow (CBF) in stroke, autoimmune mechanisms of brain damage. Widening of therapeutic window, introduction of new generation of thrombolytic medications, tele-thrombolysis and thrombolysis in mobile stroke units are discussed. In patients taking AC, the tactics of prescribing IIa and Xa factor blockers during telethrombolysis and thrombolysis are discussed. The issues of urgent correction of hemostasis in the development of ICH while taking AC, as well as the resumption of their use in the future, are considered. The issues of neuroprotection, including the combination of neuroprotection and telethrombolysis and thrombolysis, and the translation of experimental studies into clinical practice, as well as the implementation of immunomodulatory therapy are discussed.

Keywords:

stroke
penumbra
thrombolysis
reperfusion
recanalization
oral anticoagulants
autoimmunity
DAMPS
neuroprotection
immunomodulation therapy

Authors:

Gusev E.I.

Pirogov Russian National Research Medical University (Pirogov University)

Martynov M.Yu.

Pirogov Russian National Research Medical University (Pirogov University);
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

Received:

10.08.2024

Accepted:

12.08.2024

Close metadata

References:

  1. GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024;23(4):344-381.  https://doi.org/10.1016/S1474-4422(24)00038-3
  2. GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021;20(10):795-820.  https://doi.org/10.1016/S1474-4422(21)00252-0
  3. Krishnamurthi RV, Ikeda T, Feigin VL. Global, regional and country-specific burden of ischaemic stroke, intracerebral haemorrhage and subarachnoid haemorrhage: a systematic analysis of the Global Burden of Disease study 2017. Neuroepidemiology. 2020;54(2):171-179.  https://doi.org/10.1159/000506396
  4. Madsen TE, Khoury JC, Leppert M, et al. Temporal trends in stroke incidence over time by sex and age in the GCNKSS. Stroke. 2020;51(4):1070-1076. https://doi.org/10.1161/STROKEAHA.120.028910
  5. Dichgans M, Pulit SL, Rosand J. Stroke genetics: discovery, biology, and clinical applications. Lancet Neurol. 2019;18(6):587-599.  https://doi.org/10.1016/S1474-4422(19)30043-2
  6. Chojdak-Łukasiewicz J, Dziadkowiak E, Budrewicz S. Monogenic causes of strokes. Genes (Basel). 2021;12(12):1855. https://doi.org/10.3390/genes12121855
  7. Rutten-Jacobs LC, Larsson SC, Malik R, Rannikmäe K; MEGASTROKE consortium; International Stroke Genetics Consortium; et al. Genetic risk, incident stroke, and the benefits of adhering to a healthy lifestyle: cohort study of 306 473 UK Biobank participants. BMJ. 2018;363:k4168. https://doi.org/10.1136/bmj.k4168
  8. Wang K, Lei L, Li G, et al. Association between ambient particulate air pollution and soluble biomarkers of endothelial function: a meta-analysis. Toxics. 2024;12(1):76.  https://doi.org/10.3390/toxics12010076
  9. Feigin VL, Nikitin YP, Bots ML, et al. A population-based study of the associations of stroke occurrence with weather parameters in Siberia, Russia (1982-92). Eur J Neurol. 2000;7(2):171-8.  https://doi.org/10.1046/j.1468-1331.2000.00016.x
  10. van Seeters T, Hendrikse J, Biessels GJ, et al; SMART Study Group. Completeness of the circle of Willis and risk of ischemic stroke in patients without cerebrovascular disease. Neuroradiology. 2015;57(12):1247-51.  https://doi.org/10.1007/s00234-015-1589-2
  11. Mitsumura H, Miyagawa S, Komatsu T, et al. Relationship between vertebral artery hypoplasia and posterior circulation ischemia. J Stroke Cerebrovasc Dis. 2016;25(2):266-9.  https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.09.027
  12. Zhou H, Sun J, Ji X, et al. Correlation between the integrity of the circle of Willis and the severity of initial noncardiac cerebral infarction and clinical prognosis. Medicine (Baltimore). 2016;95(10):e2892. https://doi.org/10.1097/MD.0000000000002892
  13. Boot E, Ekker MS, Putaala J, et al. Ischaemic stroke in young adults: a global perspective. J Neurol Neurosurg Psychiatry. 2020;91(4):411-417.  https://doi.org/10.1136/jnnp-2019-322424
  14. Reddin C, Murphy R, Hankey GJ, et al; INTERSTROKE investigators. Association of psychosocial stress with risk of acute stroke. JAMA Netw Open. 2022;5(12):e2244836. https://doi.org/10.1001/jamanetworkopen.2022.44836
  15. Fenger-Grøn M, Paulsen Møller I, Schou Pedersen H, et al. Death of a partner and risks of ischemic stroke and intracerebral hemorrhage: a nationwide Danish matched cohort study. J Am Heart Assoc. 2020;9(23):e018763. https://doi.org/10.1161/JAHA.120.018763
  16. Holman EA, Cramer SC; STRONG Study Investigators. Lifetime and acute stress predict functional outcomes following stroke: findings from the longitudinal STRONG Study. Stroke. 2023;54(11):2794-2803. https://doi.org/10.1161/STROKEAHA.123.043356
  17. Harshfield EL, Pennells L, Schwartz JE, et al; Emerging Risk Factors Collaboration. Association between depressive symptoms and incident cardiovascular diseases. JAMA. 2020;324(23):2396-2405. https://doi.org/10.1001/jama.2020.23068
  18. Niaz D, Necyk C, Simpson SH. Depression and antecedent medication adherence in a cohort of new metformin users. Diabet Med. 2021;38(2):e14426. https://doi.org/10.1111/dme.14426
  19. Hidalgo JL, Sotos JR; DEP-EXERCISE Group. Effectiveness of physical exercise in older adults with mild to moderate depression. Ann Fam Med. 2021;19(4):302-309.  https://doi.org/10.1370/afm.2670
  20. Mc Carthy CE, Yusuf S, Judge C, et al. Sleep patterns and the risk of acute stroke: results from the INTERSTROKE international case-control study. Neurology. 2023;100(21):e2191-e2203. https://doi.org/10.1212/WNL.0000000000207249
  21. Sawadogo W, Adera T, Alattar M, et al. Association between insomnia symptoms and trajectory with the risk of stroke in the Health and Retirement Study. Neurology. 2023;101(5):e475-e488. https://doi.org/10.1212/WNL.0000000000207449
  22. Mc Carthy CE, Yusuf S, Judge C, et al. Pre-morbid sleep disturbance and its association with stroke severity: results from the international INTERSTROKE study. Eur J Neurol. 2024;31(6):e16193. https://doi.org/10.1111/ene.16193
  23. Pedersen TGB, Vinter N, Schmidt M, et al. Trends in the incidence and mortality of intracerebral hemorrhage, and the associated risk factors, in Denmark from 2004 to 2017. Eur J Neurol. 2022;29(1):168-177.  https://doi.org/10.1111/ene.15110
  24. Seiffge DJ, Goeldlin MB, Tatlisumak T, et al. Meta-analysis of haematoma volume, haematoma expansion and mortality in intracerebral haemorrhage associated with oral anticoagulant use. J Neurol. 2019;266(12):3126-3135. https://doi.org/10.1007/s00415-019-09536-1
  25. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-62.  https://doi.org/10.1016/S0140-6736(13)62343-0
  26. Yu AYX, Malo S, Svenson LW, et al. Temporal trends in the use and comparative effectiveness of direct oral anticoagulant agents versus warfarin for nonvalvular atrial fibrillation: a Canadian population-based study. J Am Heart Assoc. 2017;6(11):e007129. https://doi.org/10.1161/JAHA.117.007129
  27. Sung SF, Lai EC, Wu DP, Hsieh CY. Previously undiagnosed risk factors and medication nonadherence are prevalent in young adults with first-ever stroke. Pharmacoepidemiol Drug Saf. 2017;26(12):1458-1464. https://doi.org/10.1002/pds.4250
  28. Rêgo A, Nannoni S, Scherz A, et al. Undiagnosed major risk factors in acute ischaemic stroke patients: frequency, profile, stroke mechanisms and outcome. Eur J Neurol. 2024;31(1):e16011. https://doi.org/10.1111/ene.16011
  29. Heiss WD, Zaro Weber O. Validation of MRI determination of the penumbra by PET measurements in ischemic stroke. J Nucl Med. 2017;58(2):187-193.  https://doi.org/10.2967/jnumed.116.185975
  30. Astrup J, Siesjö BK, Symon L. Thresholds in cerebral ischemia — the ischemic penumbra. Stroke. 1981;12(6):723-5.  https://doi.org/10.1161/01.str.12.6.723
  31. Back T, Zhao W, Ginsberg MD. Three-dimensional image analysis of brain glucose metabolism-blood flow uncoupling and its electrophysiological correlates in the acute ischemic penumbra following middle cerebral artery occlusion. J Cereb Blood Flow Metab. 1995;15(4):566-77.  https://doi.org/10.1038/jcbfm.1995.70
  32. Takeda Y, Zhao L, Jacewicz M, et al. Metabolic and perfusion responses to recurrent peri-infarct depolarization during focal ischemia in the spontaneously hypertensive rat: dominant contribution of sporadic CBF decrements to infarct expansion. J Cereb Blood Flow Metab. 2011;31(9):1863-73.  https://doi.org/10.1038/jcbfm.2011.62
  33. del Zoppo GJ, Sharp FR, Heiss WD, Albers GW. Heterogeneity in the penumbra. J Cereb Blood Flow Metab. 2011;31(9):1836-51.  https://doi.org/10.1038/jcbfm.2011.93
  34. Binder NF, Glück C, Middleham W, et al. Vascular response to spreading depolarization predicts stroke outcome. Stroke. 2022;53(4):1386-1395. https://doi.org/10.1161/STROKEAHA.121.038085
  35. Cheripelli BK, Huang X, McVerry F, Muir KW. What is the relationship among penumbra volume, collaterals, and time since onset in the first 6 h after acute ischemic stroke? Int J Stroke. 2016;11(3):338-46.  https://doi.org/10.1177/1747493015620807
  36. Makris N, Chamard L, Mikkelsen IK, et al. Acute reperfusion without recanalization: Serial assessment of collaterals within 6 h of using perfusion-weighted magnetic resonance imaging. J Cereb Blood Flow Metab. 2019;39(2):251-259.  https://doi.org/10.1177/0271678X17744716
  37. Alexandrov AV, Black SE, Ehrlich LE, et al. Predictors of hemorrhagic transformation occurring spontaneously and on anticoagulants in patients with acute ischemic stroke. Stroke. 1997;28(6):1198-202.  https://doi.org/10.1161/01.str.28.6.1198
  38. Heiss WD, Huber M, Fink GR, et al. Progressive derangement of periinfarct viable tissue in ischemic stroke. J Cereb Blood Flow Metab. 1992;12(2):193-203.  https://doi.org/10.1038/jcbfm.1992.29
  39. Marchal G, Beaudouin V, Rioux P, et al. Prolonged persistence of substantial volumes of potentially viable brain tissue after stroke: a correlative PET-CT study with voxel-based data analysis. Stroke. 1996;27(4):599-606.  https://doi.org/10.1161/01.str.27.4.599
  40. Del Bigio MR, Yan HJ, Buist R, Peeling J. Experimental intracerebral hemorrhage in rats. Magnetic resonance imaging and histopathological correlates. Stroke. 1996;27(12):2312-9.  https://doi.org/10.1161/01.str.27.12.2312
  41. Stonic VA, Gusev EI, Martynov MYu, et al. New medications for treatment of hemorrhagic stroke. High-resolution MRI in evaluation of gistochrome in experimental hemorrhagic stroke. Doklady Biological Sciences. 2005;405(5):696-698 (In Russ.).
  42. Zille M, Karuppagounder SS, Chen Y, et al. Neuronal death after hemorrhagic stroke in vitro and in vivo shares features of ferroptosis and necroptosis. Stroke. 2017;48(4):1033-1043. https://doi.org/10.1161/STROKEAHA.116.015609
  43. Shao L, Chen S, Ma L. Secondary brain injury by oxidative stress after cerebral hemorrhage: recent advances. Front Cell Neurosci. 2022;16:853589. https://doi.org/10.3389/fncel.2022.853589
  44. Zazulia AR, Diringer MN, Videen TO, et al. Hypoperfusion without ischemia surrounding acute intracerebral hemorrhage. J Cereb Blood Flow Metab. 2001;21(7):804-10.  https://doi.org/10.1097/00004647-200107000-00005
  45. Tobieson L, Rossitti S, Zsigmond P, et al. Persistent metabolic disturbance in the perihemorrhagic zone despite a normalized cerebral blood flow following surgery for intracerebral hemorrhage. Neurosurgery. 2019;84(6):1269-1279. https://doi.org/10.1093/neuros/nyy179
  46. Murthy SB, Zhang C, Gupta A, et al. Diffusion-weighted imaging lesions after intracerebral hemorrhage and risk of stroke: A MISTIE III and ATACH-2 analysis. Stroke. 2021;52(2):595-602.  https://doi.org/10.1161/STROKEAHA.120.031628
  47. Tayal AH, Gupta R, Yonas H, et al. Quantitative perihematomal blood flow in spontaneous intracerebral hemorrhage predicts in-hospital functional outcome. Stroke. 2007;38(2):319-24.  https://doi.org/10.1161/01.STR.0000254492.35504.db.
  48. Morotti A, Busto G, Boulouis G, et al. Delayed perihematomal hypoperfusion is associated with poor outcome in intracerebral haemorrhage. Eur J Clin Invest. 2022;52(4):e13696. https://doi.org/10.1111/eci.13696
  49. Schuhmann MK, Kollikowski AM, März AG, et al. Danger-associated molecular patterns are locally released during occlusion in hyper-acute stroke. Brain Behav Immun Health. 2021;15:100270. https://doi.org/10.1016/j.bbih.2021.100270
  50. Przykaza Ł. Understanding the connection between common stroke comorbidities, their associated inflammation, and the course of the cerebral ischemia/reperfusion cascade. Front Immunol. 2021;12:782569. https://doi.org/10.3389/fimmu.2021.782569
  51. Haak BW, Westendorp WF, van Engelen TSR, et al. Disruptions of anaerobic gut bacteria are associated with stroke and post-stroke infection: a prospective case-control study. Transl Stroke Res. 2021;12(4):581-592.  https://doi.org/10.1007/s12975-020-00863-4
  52. Xie X, Wang L, Dong S, et al. Immune regulation of the gut-brain axis and lung-brain axis involved in ischemic stroke. Neural Regen Res. 2024;19(3):519-528.  https://doi.org/10.4103/1673-5374.380869
  53. Helmy TA, Abd-Elhady MA, Abdou M. Prediction of ischemic stroke-associated pneumonia: a comparison between 3 scores. J Stroke Cerebrovasc Dis. 2016;25(11):2756-2761. https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.07.030
  54. Chuchalin AG, Gusev EI, Martynov MYu, et al. Pulmonary insufficiency in acute stroke: risk factors and mechanisms of development. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(7):7—16. (In Russ.). https://doi.org/10.17116/jnevro20201200717
  55. Gusev EI, Skvortsova VI, Stahovskaya LV. Epidemiology of stroke In Russian Federation. S.S. Korsakov journal of neurology and psychiatry. 2003;103(8-2):4-9. (In Russ.).
  56. Gusev EI, Drapkina OM, Martynov MYu, et al. Prognostic value of blood pressure in the acute period of hemispheric ischemic stroke. Cardiovascular Therapy and Prevention. 2024;23(2):3886. (In Russ.). https://doi.org/10.15829/1728-8800-2024-3886
  57. Fan K, Zhao J, Chang H, et al. Predicting prognosis in patients with stroke treated with intravenous alteplase through the 24-h trajectory of blood pressure changes. J Clin Hypertens (Greenwich). 2021;23(9):1718-1730. https://doi.org/10.1111/jch.14331
  58. Yang P, Song L, Zhang Y, et al; ENCHANTED2/MT Investigators. Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blindedendpoint, randomised controlled trial. Lancet. 2022;400(10363):1585-1596. https://doi.org/10.1016/S0140-6736(22)01882-7
  59. Nam HS, Kim YD, Heo J, et al; OPTIMAL-BP Trial Investigators. Intensive vs conventional blood pressure lowering after endovascular thrombectomy in acute ischemic stroke: the OPTIMAL-BP randomized clinical trial. JAMA. 2023;330(9):832-842.  https://doi.org/10.1001/jama.2023.14590
  60. Ghozy S, Mortezaei A, Elfil M, et al. Intensive vs conventional blood pressure control after thrombectomy in acute ischemic stroke: a systematic review and meta-analysis. JAMA Netw Open. 2024;7(2):e240179. https://doi.org/10.1001/jamanetworkopen.2024.0179
  61. Anderson CS, Heeley E, Huang Y, et al; INTERACT2 Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368(25):2355-65.  https://doi.org/10.1056/NEJMoa1214609
  62. Ma L, Hu X, Song L, al; INTERACT3 Investigators. The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial. Lancet. 2023;402(10395):27-40.  https://doi.org/10.1016/S0140-6736(23)00806-1
  63. Li Q, Warren AD, Qureshi AI, al. Ultra-early blood pressure reduction attenuates hematoma growth and improves outcome in intracerebral hemorrhage. Ann Neurol. 2020;88(2):388-395.  https://doi.org/10.1002/ana.25793
  64. Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015;313(8):824-36.  https://doi.org/10.1001/jama.2015.0846
  65. Aguiar de Sousa D, von Martial R, Abilleira S, et al. Access to and delivery of acute ischaemic stroke treatments: A survey of national scientific societies and stroke experts in 44 European countries. Eur Stroke J. 2019;4(1):13-28.  https://doi.org/10.1177/2396987318786023
  66. Ma H, Campbell BCV, Parsons MW, et al; EXTEND Investigators. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. N Engl J Med. 2019;380(19):1795-1803. https://doi.org/10.1056/NEJMoa1813046
  67. Xiong Y, Campbell BCV, Schwamm LH, et al; TRACE-III Investigators. tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy. N Engl J Med. 2024. https://doi.org/10.1056/NEJMoa2402980
  68. Shen H, Killingsworth MC, Bhaskar SMM. Comprehensive meta-analysis of futile recanalization in acute ischemic stroke patients undergoing endovascular thrombectomy: prevalence, factors, and clinical outcomes. Life (Basel). 2023;13(10):1965. https://doi.org/10.3390/life13101965
  69. Ng FC, Churilov L, Yassi N, et al. Prevalence and significance of impaired microvascular tissue reperfusion despite macrovascular angiographic reperfusion (no-reflow). Neurology. 2022;98(8):e790-e801. https://doi.org/10.1212/WNL.0000000000013210
  70. Lee M, Kim Y, Oh MS, et al. Cerebral small vessel disease burden and futile reperfusion after endovascular treatment for patients with acute ischemic stroke. Cerebrovasc Dis. 2023;52(4):427-434.  https://doi.org/10.1159/000527020
  71. Meinel TR, Wilson D, Gensicke H, et al. Intravenous thrombolysis in patients with ischemic stroke and recent ingestion of direct oral anticoagulants. JAMA Neurol. 2023;80(3):233-243.  https://doi.org/10.1001/jamaneurol.2022.4782
  72. Kallmünzer B, Pott M, Schwab S. Letter by Kallmünzer et al Regarding Article, “Safety of intravenous thrombolysis among patients taking direct oral anticoagulants: a systematic review and meta-analysis”. Stroke. 2020;51(7):e130-e131. https://doi.org/10.1161/STROKEAHA.120.029631
  73. Karaszewski B, Szczyrba S, Jabłoński B, et al. Case report: First treatment of acute ischaemic stroke in a patient on active rivaroxaban therapy using andexanet alfa and rtPA combined with early complete recovery. Front Neurol. 2023;14:1269651. https://doi.org/10.3389/fneur.2023.1269651
  74. Mowla A, Memon A, Razavi SM, et al. Safety of intravenous thrombolysis for acute ischemic stroke in patients taking warfarin with subtherapeutic INR. J Stroke Cerebrovasc Dis. 2021;30(5):105678. https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.105678
  75. Chausson N, Soumah D, Aghasaryan M, et al. Reversal of vitamin K antagonist therapy before thrombolysis for acute ischemic stroke. Stroke. 2018;49(10):2526-2528. https://doi.org/10.1161/STROKEAHA.118.020890
  76. Burgos AM, Saver JL. Evidence that tenecteplase is noninferior to alteplase for acute ischemic stroke: meta-analysis of 5 randomized trials. Stroke. 2019;50(8):2156-2162. https://doi.org/10.1161/STROKEAHA.119.025080
  77. Li S, Gu HQ, Li H, al; RAISE Investigators. Reteplase versus Alteplase for acute ischemic stroke. N Engl J Med. 2024 Jun 14.  https://doi.org/10.1056/NEJMoa2400314
  78. Song H, Wang Y, Ma Q, et al; PROST collaborative group. efficacy and safety of recombinant human prourokinase in the treatment of acute ischemic stroke within 4.5 hours of stroke onset: a phase 3 randomized clinical trial. JAMA Netw Open. 2023;6(7):e2325415. https://doi.org/10.1001/jamanetworkopen.2023.25415
  79. Gusev EI, Martynov MY, Nikonov AA, et al; FRIDA Study Group. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset In Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial. Lancet Neurol. 2021;20(9):721-728.  https://doi.org/10.1016/S1474-4422(21)00210-6
  80. Gusev EI, Martynov MYu, Shamalov NA, et al. Nonimmunogenic staphylokinase in the treatment of acute ischemic stroke (FRIDA trial results). S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(7):56-65. (In Russ.). https://doi.org/10.17116/jnevro202212207156
  81. van der Ende NAM, Roozenbeek B, Smagge LEM, et al; DUMAS Investigators. Safety and efficacy of dual thrombolytic therapy with mutant prourokinase and small bolus alteplase for ischemic stroke: a randomized clinical trial. JAMA Neurol. 2023;80(7):714-722.  https://doi.org/10.1001/jamaneurol.2023.1262
  82. Migliavacca M, Correa-Paz C, Pérez-Mato M, et al. Thrombolytic therapy based on lyophilized platelet-derived nanocarriers for ischemic stroke. J Nanobiotechnology. 2024;22(1):10.  https://doi.org/10.1186/s12951-023-02206-5
  83. Komakula S, Bhatia R, Sahib A, et al. Safety and efficacy of N-acetylcysteine (NAC) as an adjunct to standard treatment in patients with acute ischemic stroke: a randomized controlled pilot trial (NACTLYS). Sci Rep. 2024;14(1):1103. https://doi.org/10.1038/s41598-023-49054-9
  84. Nimjee SM, Dornbos D3rd, Pitoc GA, et al. Preclinical development of a vWF aptamer to limit thrombosis and engender arterial recanalization of occluded vessels. Mol Ther. 2019;27:1228—1241. https://doi.org/10.1016/j.ymthe.2019.03.016
  85. Barkova TV, Alasheev AM, Belkin AA, et al. The efficacy and safety of telethrombolysis in a newly opened stroke unit. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118 (12-2):70-74. (In Russ.). https://doi.org/10.17116/jnevro201811812270
  86. Hubert GJ, Santo G, Vanhooren G, et al. Recommendations on telestroke in Europe. Eur Stroke J. 2019;4(2):101-109.  https://doi.org/10.1177/2396987318806718
  87. Soun JE, Chow DS, Nagamine M, et al. Artificial intelligence and acute stroke imaging. AJNR Am J Neuroradiol. 2021;42(1):2-11.  https://doi.org/10.3174/ajnr.A6883
  88. Müller-Barna P, Hubert GJ, Boy S, et al. TeleStroke units serving as a model of care in rural areas: 10-year experience of the TeleMedical project for integrative stroke care. Stroke. 2014;45(9):2739-44.  https://doi.org/10.1161/STROKEAHA.114.006141
  89. Wilcock AD, Schwamm LH, Zubizarreta JR, et al. Reperfusion treatment and stroke outcomes in hospitals with telestroke capacity. JAMA Neurol. 2021;78(5):527-535.  https://doi.org/10.1001/jamaneurol.2021.0023
  90. Zhao H, Coote S, Easton D, et al. Melbourne mobile stroke unit and reperfusion therapy: greater clinical impact of thrombectomy than thrombolysis. Stroke. 2020;51(3):922-930.  https://doi.org/10.1161/STROKEAHA.119.027843
  91. Bluhm S, Schramm P, Spreen-Ledebur Y, et al. Potential effects of a mobile stroke unit on time to treatment and outcome in patients treated with thrombectomy or thrombolysis: A Danish-German cross-border analysis. Eur J Neurol. 2024:e16298. https://doi.org/10.1111/ene.16298
  92. Ebinger M, Siegerink B, Kunz A, et al; Berlin prehospital or usual delivery in stroke care (b_proud) study group. Association between dispatch of mobile stroke units and functional outcomes among patients with acute ischemic stroke in Berlin. JAMA. 2021;325(5):454-466.  https://doi.org/10.1001/jama.2020.26345
  93. Turc G, Hadziahmetovic M, Walter S, et al. Comparison of mobile stroke unit with usual care for acute ischemic stroke management: a systematic review and meta-analysis. JAMA Neurol. 2022;79(3):281-290.  https://doi.org/10.1001/jamaneurol.2021.5321
  94. Dabi A, Koutrouvelis AP. Reversal strategies for intracranial hemorrhage related to direct oral anticoagulant medications. Crit Care Res Pract. 2018;2018:4907164. https://doi.org/10.1155/2018/4907164
  95. Connolly SJ, Sharma M, Cohen AT, et al; ANNEXA-I investigators. Andexanet for Factor Xa inhibitor-associated acute intracerebral hemorrhage. N Engl J Med. 2024;390(19):1745-1755. https://doi.org/10.1056/NEJMoa2313040
  96. Costa OS, Connolly SJ, Sharma M, et al. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis. Crit Care. 2022;26(1):180.  https://doi.org/10.1186/s13054-022-04043-8
  97. Pan R, Cheng J, Lai K, et al. Efficacy and safety of prothrombin complex concentrate for vitamin K antagonist-associated intracranial hemorrhage: a systematic review and meta-analysis. Neurol Sci. 2019;40(4):813-827.  https://doi.org/10.1007/s10072-019-3726-x
  98. Tsai CT, Liao JN, Chiang CE, et al. Association of ischemic stroke, major bleeding, and other adverse events with Warfarin use vs non-vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation with a history of intracranial hemorrhage. JAMA Netw Open. 2020;3(6):e206424. https://doi.org/10.1001/jamanetworkopen.2020.6424
  99. Biffi A, Kuramatsu JB, Leasure A, et al. Oral anticoagulation and functional outcome after intracerebral hemorrhage. Ann Neurol. 2017;82(5):755-765.  https://doi.org/10.1002/ana.25079
  100. Li YG, Lip GYH. Anticoagulation resumption after intracerebral hemorrhage. Curr Atheroscler Rep. 2018;20(7):32.  https://doi.org/10.1007/s11883-018-0733-y
  101. Astrup J. Energy-requiring cell functions in the ischemic brain. Their critical supply and possible inhibition in protective therapy. J Neurosurg. 1982;56(4):482-97.  https://doi.org/10.3171/jns.1982.56.4.0482
  102. Fisher M, Feuerstein G, Howells DW, et al; STAIR Group. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009;40(6):2244-50.  https://doi.org/10.1161/STROKEAHA.108.541128
  103. Paul S, Candelario-Jalil E. Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies. Exp Neurol. 2021;335:113518. https://doi.org/10.1016/j.expneurol.2020.113518
  104. O’Collins VE, Macleod MR, Donnan GA, Howells DW. Evaluation of combination therapy in animal models of cerebral ischemia. J Cereb Blood Flow Metab. 2012;32(4):585-97.  https://doi.org/10.1038/jcbfm.2011.203
  105. Chrostek MR, Fellows EG, Crane AT, et al. Efficacy of stem cell-based therapies for stroke. Brain Res. 2019;1722:146362. https://doi.org/10.1016/j.brainres.2019.146362
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.